Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

Epidermal growth factor receptor (EGFR)-targeted cancer therapy such as anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors have demonstrated clinical efficacy. However, there remains a medical need addressing limitations of these therapies, which include a narrow therapeutic window mainl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wingert, Susanne, Reusch, Uwe, Knackmuss, Stefan, Kluge, Michael, Damrat, Michael, Pahl, Jens, Schniegler-Mattox, Ute, Mueller, Thomas, Fucek, Ivica, Ellwanger, Kristina, Tesar, Michael, Haneke, Torsten, Koch, Joachim, Treder, Martin, Fischer, Wolfgang, Rajkovic, Erich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331026/
https://www.ncbi.nlm.nih.gov/pubmed/34325617
http://dx.doi.org/10.1080/19420862.2021.1950264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331026/
https://www.ncbi.nlm.nih.gov/pubmed/34325617
http://dx.doi.org/10.1080/19420862.2021.1950264

Ejemplares similares